Clinical Trials News
September 10th, 2009
GlaxoSmithKline recently advised the public that the US FDA’s Vaccines and Related Biological Products Advisory Committee voted that Ceravix, the company’s cervical cancer vaccine, presented data that substantiates the efficacy and safety of the treatment.
August 19th, 2009
A recent study proclaims that patients who require a blood stem-cell transplant may be able to lessen the risk of graft-versus-host disease (GVHD - transplanted materials attack the body), thanks to ant-T-cell globulin treatment.
August 17th, 2009
After Benlysta achieved the primary endpoint in Bliss - 52, Human Genome Sciences, is pleased report that the first two pivotal Phase 3 trials involving patients with serologically active systematic lupus erythematous has been completed. The results have began to prove that Benlysta may in fact possess the potential to become the first approved systematic lupus treatment in decades.
August 17th, 2009
The US FDA has approved Saphris sublingual tablets for the acute therapy of schizophrenic adults, as well as the acute therapy of manic or mixed bipolar I disorder, with or without adult psychotic attributes. Saphris is endorsed for first-line therapy, and is the first prescription drug to receive primary consent for both of these symptoms concurrently.
August 13th, 2009
Specialty pharmaceutical company, who specializes in the generation of revolutionary products to treat neurological and psychiatric diseases, publicizes top-line results from the Phase III Zelrix clinical tria
August 11th, 2009
Sanofi-aventis recently publicized the release of an Expert Statement issued by a board of multidisciplinary, internationally acclaimed experts, which follows an in-depth evaluation of the recent publications of registry analyses with Lantus in Diabetologia.
August 11th, 2009
The National Heart, Lung and Blood Institute (NHLBI) has halted a clinical trial involving drug treatment tests for pulmonary hypertension in adults who suffer from sickle cell disease.
August 11th, 2009
Array BioPharma Inc. has recently notified the public of their Phase 1 favorable top-line data clinical trial, conducted with a group Type 2 diabetes patients and their small molecule glucokinase activator (GKA), ARRY-403
August 7th, 2009
Baxter International has recently announced that they have finished the production of their first commerical batches of CELVAPAN A/H1N1 pandemic vaccine.
August 7th, 2009
The US FDA has recently approved Invega Sustenna extended-release injectable suspension for acute and maintenance therapy of adult schizophrenia. Invega Sustenna is the first US approved once a month injectable, long-acting, atypical antipsychotic.
